COVIG-19

Serial Number 90218133
Registration 6437981
700

Registration Progress

Application Filed
Sep 28, 2020
Under Examination
Approved for Publication
May 18, 2021
Published for Opposition
May 18, 2021
Registered
Aug 3, 2021

Trademark Image

COVIG-19

Basic Information

Serial Number
90218133
Registration Number
6437981
Filing Date
September 28, 2020
Registration Date
August 3, 2021
Published for Opposition
May 18, 2021
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 3, 2021
Registration
Registered
Classes
005 042 044

Rights Holder

Takeda Pharmaceuticals International AG

99
Address
Thurgauerstrasse 130
Glattpark-Opfikon 8152
CH

Ownership History

Takeda Pharmaceuticals International AG

Original Applicant
99
Glattpark-Opfikon CH

Takeda Pharmaceuticals International AG

Owner at Publication
99
Glattpark-Opfikon CH

Takeda Pharmaceuticals International AG

Original Registrant
99
Glattpark-Opfikon CH

Legal Representation

Attorney
Karl M. Zielaznicki, Esq.

USPTO Deadlines

Next Deadline
744 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-08-03)
Due Date
August 03, 2027
Grace Period Ends
February 03, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

28 events
Date Code Type Description Documents
Aug 3, 2021 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
May 18, 2021 PUBO A PUBLISHED FOR OPPOSITION Loading...
May 18, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 28, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 14, 2021 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Apr 14, 2021 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Apr 14, 2021 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Apr 14, 2021 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Apr 14, 2021 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 13, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 13, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 7, 2021 ALIE A ASSIGNED TO LIE Loading...
Jan 7, 2021 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Jan 4, 2021 CNSL R SUSPENSION LETTER WRITTEN Loading...
Jan 4, 2021 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Jan 4, 2021 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Dec 23, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 22, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Dec 22, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 30, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Oct 30, 2020 GNRT F NON-FINAL ACTION E-MAILED Loading...
Oct 30, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Oct 29, 2020 APET A ASSIGNED TO PETITION STAFF Loading...
Oct 29, 2020 PCGR O PETITION TO DIRECTOR GRANTED Loading...
Oct 29, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 28, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 12, 2020 TPDR I TEAS PETITION TO DIRECTOR RECEIVED Loading...
Oct 1, 2020 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment and immunization of coronavirus diseases; blood for medical purposes; blood components for medical purposes, in particular blood plasma
First Use Anywhere: 0
First Use in Commerce: 0
Class 042
Scientific research services in the field of pharmaceuticals related to the treatment and immunization of coronavirus diseases; blood analysis services
First Use Anywhere: 0
First Use in Commerce: 0
Class 044
Blood bank services; medical services and paramedical services, namely, collection of blood, and providing transfusions of blood and blood components
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005 042 044